文献速递瓣膜外科

经导管技术对主动脉瓣置换手术量、结局与费用的影响

Impact of Transcatheter Technology on Surgical Aortic Valve Replacement Volume, Outcomes, and Cost.
PubMed 文献 · Ann Thorac Surg · 2017-04-24

该研究基于弗吉尼亚心脏服务数据库11565例2002至2015年行外科主动脉瓣置换(SAVR)的患者,按TAVR前、早期和商业化时代分层。结果显示SAVR手术量未降反增,STS预测风险下降,死亡率与主要并发症在商业化TAVR时代最低,但总费用持续上升。

要点

  • TAVR时代SAVR手术量未减少,全州年手术量中位数从722例增至940例。
  • SAVR患者STS预测死亡率从3.7%降至2.4%,商业化TAVR时代结局最佳。
  • SAVR总费用从42835美元升至54710美元,但仍低于TAVR。

核心结论

  • 目前SAVR手术量未受TAVR引入影响,SAVR结局持续改善,可能与高危患者可选择经导管方案有关。
  • 尽管SAVR费用上升,开放手术相比TAVR仍具显著成本优势。

研究设计与样本

  • 回顾性队列研究,纳入弗吉尼亚心脏服务数据库2002至2015年11565例SAVR患者(伴或不伴冠脉搭桥)。
  • 按TAVR前时代(2002-2008,n=5113)、早期TAVR时代(2009-2011,n=2709)和商业化TAVR时代(2012-2015,n=3743)分层。
  • 采用单变量分析比较患者特征、结局和资源利用。

主要发现

  • 全州SAVR年手术量中位数:TAVR前722例、早期TAVR 892例、商业化TAVR 940例(p=0.005)。
  • SAVR患者STS预测死亡率:TAVR前3.7%、早期TAVR 2.6%、商业化TAVR 2.4%(p<0.0001)。
  • 死亡率:TAVR前3.9%、早期TAVR 4.3%、商业化TAVR 3.2%(p=0.05)。
  • 主要并发症发生率:TAVR前21.2%、早期TAVR 20.5%、商业化TAVR 15.2%(p<0.0001)。
  • 商业化TAVR时代死亡和主要并发症的观察/预期比值均为0.9;总费用从42835美元升至51923美元再至54710美元(p<0.0001)。

临床怎么用

  • TAVR推广后SAVR仍保持增长,应继续作为主动脉瓣病变的重要治疗选项。
  • 商业化TAVR时代SAVR风险调整结局更优,提示患者选择向低风险偏移。
  • 需关注SAVR费用上升趋势,但开放手术成本仍低于TAVR。

局限性

  • 回顾性数据库研究,仅行单变量分析,未校正混杂因素。
  • 数据来自单一州质量联盟,外推性受限。
  • 未报告TAVR具体例数及SAVR与TAVR的直接成本比较细节。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Transcatheter aortic valve replacement (TAVR) represents a disruptive technology that is rapidly expanding in use. We evaluated the effect on surgical aortic valve replacement (SAVR) patient selection, outcomes, volume, and cost. METHODS: A total of 11,565 patients who underwent SAVR, with or without coronary artery bypass grafting (2002 to 2015), were evaluated from the Virginia Cardiac Services Quality Initiative database. Patients were stratified by surgical era: pre-TAVR era (2002 to 2008, n = 5,113), early-TAVR era (2009 to 2011, n = 2,709), and commercial-TAVR era (2012 to 2015, n = 3,743). Patient characteristics, outcomes, and resource utilization were analyzed by univariate analyses. RESULTS: Throughout the study period, statewide SAVR volumes increased with median volumes of pre-TAVR: 722 cases/year, early-TAVR: 892 cases/year, and commercial-TAVR: 940 cases/year (p = 0.005). Implementation of TAVR was associated with declining Society of Thoracic Surgeons predicted risk of mortality among SAVR patients (3.7%, 2.6%, and 2.4%; p < 0.0001), despite increasing rates of comorbid disease. The mortality rate was lowest in the current commercial-TAVR era (3.9%, 4.3%, and 3.2%; p = 0.05), and major morbidity decreased throughout the time period (21.2%, 20.5%, and 15.2%; p < 0.0001). The lowest observed-to-expected ratios for both occurred in the commercial-TAVR era (0.9 and 0.9, respectively). Resource utilization increased generally, including total cost increases from $42,835 to $51,923 to $54,710 (p < 0.0001). CONCLUSIONS: At present, SAVR volumes have not been affected by the introduction of TAVR. The outcomes for SAVR continue to improve, potentially due to availability of transcatheter options for high-risk patients. Despite rising costs for SAVR, open approaches still provide a significant cost advantage over TAVR.

来源:Ann Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Hawkins RB, Downs EA, Johnston LE, et al. Impact of Transcatheter Technology on Surgical Aortic Valve Replacement Volume, Outcomes, and Cost. Ann Thorac Surg. 2017. PMID: 28450137. doi:10.1016/j.athoracsur.2017.02.039

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。